DGAP-News: Biotest AG: Biotest AG opens three further plasmapheresis centers in Hungary and the USA
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest AG opens three further plasmapheresis centers in
Hungary and the USA
11.10.2013 / 09:05
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG opens three further plasmapheresis centers in Hungary and the
USA
- Inauguration opening of new collection center in Budapest marks
doubling of capacities in Hungary
- Two new centers already opened in USA in 2013, with two additional
centers to follow in Florida
Dreieich, October 11, 2013 - Today, Biotest is celebrating the opening of
its second plasmapheresis center in Budapest. The center, one of the most
modern of its type in Europe, is located in the newly-built Corvin shopping
center situated in the city's heart, providing space for up to 35 donor
beds across an area of around 800 m². The company is thereby boosting its
plasma sourcing capacities and continuing to grow as part of its successful
expansion activities.
The first plasmapheresis center in Budapest was opened in 2009 by
Plazmaszolgálat Kft., the subsidiary of Plasma Service Europe GmbH that was
newly founded at that time and is in turn wholly-owned by Biotest AG. 'The
success of the first center confirmed our expectations entirely. Based on
the experience and knowledge we gained there, we are very pleased to open a
further collection center in the metropolis of Budapest. With our Hungarian
subsidiary celebrating its 25th anniversary today, Hungary is an optimal
location offering good infrastructure and an excellent educational level,
especially in the medical area,' as Prof. Gregor Schulz, CEO of Biotest AG
underscored. The plasma collected there undergoes further processing
exclusively at Biotest. With this capacity expansion, the company is able
to serve the Hungarian market exclusively with products extracted from
Hungarian plasma.
Biotest is also charting continuous growth in the USA. Twelve
plasmapheresis centers were in operation there at the end of 2012, of which
eleven stations are already operational seven days a week. The company has
continued to expand its plasma collection activities in the USA during the
course of 2013 to date and has already opened two new centers in Florida,
one in Orlando and the other in Melbourne. Moreover, a new center in Royal
Palm Beach, Florida, will be followed by a further center in the course of
the next nine months. With these additions, Biotest will soon be operating
16 plasmapheresis centers in the USA. Prof. Schulz explains the strategic
reasons for the expansion as follows: 'With the expansion of our own plasma
collection capacities we are responding to continued high demand for the
resultant end-products. With a high degree of our own supply sourcing, we
are protecting ourselves against price and supply fluctuations on the
global market, guaranteeing sufficient supplies of high-quality plasma at
all times.' Regularly conducted audits at all centers ensure that the high
statutory and internal quality standards are fully met at all times, also
during this growth phase.
Human blood plasma is the basic material to produce plasma protein
preparations that are used to treat various diseases of the immune system
and the hematopoietic (blood-forming) system, as well as in emergency
medicine. Biotest ranks as one of the world's sixth largest plasma protein
product manufacturing groups.
Disclaimer
This document contains forward-looking statements about macroeconomic
trends as well as about the business position, results of operations,
financial position and net assets of Biotest AG and of its subsidiaries.
These statements are based on the company's current plans, estimates,
forecasts and expectations, and to this extent are subject to risks and
uncertainty factors that could mean that actual trends diverges from
expected trends. These forward-looking statements are valid only at the
time when this document is published. Biotest does not intend to update the
forward-looking statements, and enters into no such related obligation.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic medicines. With
a value chain that spans preclinical and clinical development through to
global marketing, Biotest specializes predominantly on the clinical
immunology, hematology as well as intensive and emergency medicine
application areas. In its plasma protein portfolio Biotest develops and
markets immunoglobulins, clotting factors and albumins which are produced
on the basis of human blood plasma, and which are utilized in diseases of
the immune system or of the hematopoietic (blood-building) systems. Biotest
also develops monoclonal antibodies, including for the rheumatoid arthritis
and hematologic cancer indications. Biotest employs more than 1,700 staff
worldwide. The preference shares of Biotest AG are listed in Deutsche
Börse's SDAX equity index.
Biotest AG, Landsteinerstrasse 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit, Telephone: +49 (0) 6103 801-4406,
E-mail: investor_relations(at)biotest.de
Fax: +49 (0) 6103 801-347
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard
Regulated Unofficial Market (OTC): Berlin-Bremen, Düsseldorf, Frankfurt,
Hamburg, Hannover, Munich, Stuttgart
End of Corporate News
---------------------------------------------------------------------
11.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
234231 11.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.10.2013 - 09:05 Uhr
Sprache: Deutsch
News-ID 305010
Anzahl Zeichen: 6025
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 472 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest AG opens three further plasmapheresis centers in Hungary and the USA"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
